ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Kidney Xenotransplantation from Genetically Engineered Pigs to Baboons with FDA-Approved Immunosuppressive Therapy

T. Yamamoto1, H. Hara1, J. Foote1, E. C. Klein2, H. J. Schuurman3, L. Wang1, Q. Li1, H. Zhou1, J. Li1, J. A. Tector1, Z. Zhang2, M. Ezzelarab2, R. Lovingood1, D. Ayares4, D. E. Eckhoff1, D. K. Cooper1, H. Iwase1

1University of Alabama at Birmingham, Birmingham, AL, 2University of Pittsburgh, Pittsburgh, PA, 3Schubiomed Consultancy, Utrecht, Netherlands, 4Revivicor, Blacksburg, VA

Meeting: 2019 American Transplant Congress

Abstract number: 272

Keywords: Immunosuppression, Kidney transplantation, Pig, Xenoreactive antibodies

Session Information

Session Name: Concurrent Session: Xenotransplantation

Session Type: Concurrent Session

Date: Monday, June 3, 2019

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:30pm-3:42pm

Location: Room 310

*Purpose: Genetically-engineered pigs might present a solution to the critical shortage of organs for clinical transplantation. The aims of this study were to evaluate the efficacy of FDA-approved immunosuppressive agents in pig-to-baboon kidney xenotransplantation, and compare the results with those achieved using an anti-CD40mAb-based regimen.

*Methods: Ten kidney transplants were carried out in baboons using GTKO/CD46 pigs with various other genetic manipulations aimed at controlling coagulation dysregulation. Immunosuppressive therapy consisted of induction with ATG and anti-CD20mAb, and maintenance with either (i) regimens using only FDA-approved drugs (tacrolimus + abatacept [CTLA4-Ig] or tacrolimus + rapamycin or mycophenolate mofetil) (GpA, n=5) or (ii) an anti-CD40 mAb + rapamycin regimen (GpB, n=5). (All 10 baboons received corticosteroids, IL-6R blockade [tocilizumab], and TNF-α blockade [etanercept].) Baboons were followed by clinical/laboratory monitoring of kidney function and coagulation/inflammatory/immune parameters. At euthanasia, morphologic and immunohistochemical studies were performed on the kidney grafts.

*Results: One GpB baboon was euthanized on day 4 for acute gastric dilatation, and was excluded from analysis. The mean survival in GpB (n=4) was 181+/-40.5 days (median 186 days), which was significantly longer than in GpA (15+/-5.0 days; median 13 days) (p<0.01). All GpA baboons were euthanized for antibody-mediated rejection, whereas 3 of 4 of GpB were euthanized for infectious complications. At euthanasia, the serum creatinine was not significantly different between the two groups (GpA 1.78+/-0.45 vs GpB 2.18+/-0.91mg/dl). Only GpA baboons developed features of consumptive coagulopathy. On histopathological examination of the grafts, the incidence of thrombotic microangiopathic glomerulopathy, glomerular/interstitial thrombi, arterial vasculitis, and peritubular capillary inflammation was significantly higher in GpA than in GpB (p<0.05). There was a significant negative correlation between all of the histopathological features of thrombotic microangiopathy and changes in coagulation parameters (platelet count and plasma fibrinogen).

*Conclusions: Our data suggest that regimens based on current FDA-approved immunosuppressive agents may be insufficient to prevent immune-mediated genetically-engineered pig kidney graft injury even when the grafts express a human coagulation-regulatory protein. However, analogues of anti-CD40 mAb (which achieved significantly longer survival) are currently in phase2 clinical trials.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Yamamoto T, Hara H, Foote J, Klein EC, Schuurman HJ, Wang L, Li Q, Zhou H, Li J, Tector JA, Zhang Z, Ezzelarab M, Lovingood R, Ayares D, Eckhoff DE, Cooper DK, Iwase H. Kidney Xenotransplantation from Genetically Engineered Pigs to Baboons with FDA-Approved Immunosuppressive Therapy [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/kidney-xenotransplantation-from-genetically-engineered-pigs-to-baboons-with-fda-approved-immunosuppressive-therapy/. Accessed May 12, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences